Process of Preparation of Substituted Tetrafluorobenzylaniline Compound and Its Pharmaceutically Approved Salts
AssigneeChoongwae Pharma Corporation
InventorsTae-Seop Hwang, Hyun-Gyu Kim
Life of this patent
Estimating the term…
Abstract
This invention relates to a method for preparing tetrafluorobenzyl-5-aminosalicylic acid derivative and its pharmaceutically acceptable salt compounds. In particular, this invention relates to a method for preparing tetrafluorobenzyl-5-aminosalicylic acid derivative and its pharmaceutically acceptable salts by using tetrafluorobenzilidine-5-aminosalicylic acid derivative as an intermediate.
Claims11
A process for preparing tetrafluorobenzyl-5-aminosalicylic acid derivative represented by Chemical Formula I and its pharmaceutically acceptable salt. The process is comprised of the following steps:
- a) oxidation of tetrafluorobenzyl alcohol, represented by Chemical Formula 1, to tetrafluorobenzaldehyde, represented by Chemical Formula 2;
- b) conversion of tetrafluorobenzaldehyde to tetrafluorobenzilidine-5-aminosalicylic acid derivative, represented by Chemical Formula II, via dehydration-condensation reaction between tetrafluorobenzaldehyde and 5-amino-salicylic acid, represented by Chemical Formula 3, and
- c) hydrogenation of tetrafluorobenzilidine-5-aminosalicylic acid derivative to tetrafluorobenzyl-5-aminosalicylic acid derivative, represented by Chemical Formula I.
- Wherein, M+ represents lithium, sodium or potassium;
- and R1, R2 and R3 may, independently of one another, be hydrogen or halogen
2-hydroxy-5-[(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzilidine)-amino]benzoic acid.
Potassium 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoate.
Lithium 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoate.
Sodium 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoate.
Oral preparation comprised of potassium 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoate.
Oral preparation comprised of lithium 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoate.
Oral preparation comprised of sodium 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoate.
A process for preparing tetrafluorobenzyl-5-aminosalicylic acid derivative represented by chemical formula I and its pharmaceutically acceptable salt, wherein the tetrafluorobenzyl-5-aminosalicylic acid derivative is prepared through hydrogenating tetrafluorobenzilidine-5-aminosalicylic acid derivative represented by chemical formula II.
- Wherein, M+ represents lithium, sodium or potassium;
- and R1, R2 and R3 may, independently of one another, be hydrogen or halogen.
Dependencies are inferred from the claim text.